Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Japanese CSO Market Overview 2016 - Research and Markets

Research and Markets
Posted on: 01 Nov 16

Research and Markets has announced the addition of the "The Overview of Japanese CSO Market ver2016" report to their offering.

The report explains about the CSO market situation in Japan. The readers will be able to understand overall market trend, as well as detailed information such as major CSO players, the reason why there are so many MR in Japan, and the future outlook.

The number of MR in Japan in 2015 was 64,135. CSO saw 3.7% decrease, which was the first time, while it had been increasing in the pat years. Some of pharmaceutical companies decreased the number of MR, mainly by cutting contract MR, due to the rationalization caused by slow domestic sales. Although CSO currently accounts for only 6% share of the total, it has grown by 20%+ over the last several years.

Japanese companies normally prefer to use internal resources. Initially, non Japanese pharma started to use contract MR. Since then, it has gradually widespread to Japanese large sized pharma, and now we can also see increasing Contract MR even in small and mid sized companies. CSO business has been gaining presence over time.

While companies still hesitate to decrease the total number of sales force, they will also see the difficulty to pool large sized of internal resources. As a result, firms will likely bridge this gap by utilizing temporary staff and contract MR. The shift towards contract MR continues, primarily at foreign firms, but Japanese pharmaceutical manufacturers will also follow. Therefore, we expect CSO market will continue to expand for a while.

Without having enough block busters in the market, many of firms will face the operational challenge soon, and they will have to see downsizing the organizations. On the other hand, new entrants will be able to enjoy the market entry with fairly light internal resources, as long as they have products to be launched in Japan. That would be really one of the rare game changing times to pharmaceutical companies, and how a company cope with this opportunity will shape its organization's future.

Key Topics Covered:

1. Summary

2. Scope Discussed

3. Medical Representative

4. Number of MR

5. Number of MR by Company

6. Industry Body

7. CSO Market Size

8. Related Regulation

9. Major CSO Companies

10. Increasing Contract MR

11. Why So Many MR in Japan?

12. Curbing Extreme Sales Tactics

13. Business & HR Strategy at Foreign Firms in Japan

14. Declining MR's Presence

15. Future Outlook

Companies Mentioned

- Quintiles

- inVentiv

- EP PharmaLine

- M3 Marketing

- Cimic Ashfield

For more information about this report visit

View source version on

Business Wire

Last updated on: 01/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.